【新整理】慢性乙型肝炎患者管理(英文版)-資料下載頁
2024-11-19 00:18本頁面
【正文】 hronic Hepatitis B,Early monitoring of the virologic response to therapy in chronic hepatitis B treated with oral nucleos(t)ides is essential… Use of this roadmap should permit improved individualized ontreatment management designed to enhance longterm patient outcomes,1.Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, EstebanMur R, Gane E, Jacobson IM, Lim SG, Naoumov NN, Marcellin P, Piratvisuth T, Zoulim F. Clin Gastroenterol Hepatol. In press.,38,Adapted form: Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, EstebanMur R, Gane E, Jacobson IM, Lim SG, Naoumov NN, Marcellin P, Piratvisuth T, Zoulim F. Clin Gastroenterol Hepatol. In press.,Start Telbivudine,Early Virologic Response Efficacy at Week 24,PCR Negative (300 copies/mL),HBV DNA 300 copies/mL to 10，000 copies/mL,HBV DNA 10，000 copies/mL,Assessment of Primary Response at week 12,Maintain Telbivudine,How May the HBV Treatment Roadmap be Applied to Telbivudine Treatment?,39,Viral Load Achieved by Week 24: Telbivudine vs. Lamivudine,Di Bisceglie A, et al. Presented at AASLD 2006,HBeAg Positive,HBeAg Negative,*,*,* P 0.05,40,Telbivudine Is A Good Option for Therapy for HBeAgPositive Patients,49% of Telbivudine Treated Patients Achieve PCR Negativity (≤300 copies/mL) at Week 24,86% PCR Negative Week 104,49% Seroconversion Week 104,2% Resistance Week 92,Baseline ALT ≥ 2 x ULN N=558,85% ALT Normalization Week 104,41,Telbivudine Is A Good Option for Therapy for HBeAgNegative Patients,80% of Telbivudine Treated Patients Achieve PCR Negativity (≤300 copies/mL) at Week 24,88% PCR Negative Week 104 N=78/86,2% Resistance at 92 weeks,49% Seroconversion Week 104,All telbivudinetreated HBeAgNegative Patients N=588,42,Start Telbivudine,Early Virologic Response Efficacy at Week 24,HBV DNA PCR Negative (300 copies/mL),HBV DNA ≥300–10,000 copies/mL,HBV DNA 10，000 copies/mL,Maintain Telbivudine Week 52 Monitor HBV DNA closely,How May the HBV Treatment Roadmap be Applied to Telbivudine Treatment?,If PCR Negative Maintain Telbivudine Monotherapy,If PCR Positive revise treatment strategy,Adapted form: Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, EstebanMur R, Gane E, Jacobson IM, Lim SG, Naoumov NN, Marcellin P, Piratvisuth T, Zoulim F. Clin Gastroenterol Hepatol. In press.,43,Start Telbivudine,Early Virologic Response Efficacy at Week 24,PCR Negative (300 copies/mL),HBV DNA ≥300–10,000 copies/mL,HBV DNA 10,000 copies/mL,Assessment of Primary Response at week 12,How May the HBV Treatment Roadmap be Applied to Telbivudine Treatment?,Revise treatment strategy,Adapted form: Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, EstebanMur R, Gane E, Jacobson IM, Lim SG, Naoumov NN, Marcellin P, Piratvisuth T, Zoulim F. Clin Gastroenterol Hepatol. In press.,44,Thank you for your attenti
醫(yī)療健康相關(guān)推薦
鄂ICP備17016276號-1